The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Carrick Therapeutics; Luminex
Research Funding - Lilly; Pfizer
Longitudinal circulating tumor DNA (ctDNA) whole-exome sequencing (WES) in the phase Ib/II trial of palbociclib and bazedoxifene reveals genomic dynamics and clonal evolution with the acquisition of treatment resistance in hormone receptor-positive, HER2-negative (HR+ HER2-), advanced breast cancer (ABC).
 
Albert Grinshpun
No Relationships to Disclose
 
Junko Tsuji
No Relationships to Disclose
 
Tianyu Li
No Relationships to Disclose
 
Douglas Russo
No Relationships to Disclose
 
Leilani Anderson
No Relationships to Disclose
 
Rebecca Rees
No Relationships to Disclose
 
Carrie Cibulskis
No Relationships to Disclose
 
Ignaty Leshchiner
Leadership - Ennov1
Stock and Other Ownership Interests - Ennov1
Consulting or Advisory Role - Ennov1; Kojin Therapeutics (I); PACT Pharma
 
Chip Stewart
No Relationships to Disclose
 
Nadine M. Tung
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
 
Ian E. Krop
Employment - Freeline Therapeutics (I); PureTech (I)
Leadership - Freeline Therapeutics (I); PureTech (I)
Stock and Other Ownership Interests - Freeline Therapeutics (I); PureTech (I)
Honoraria - AstraZeneca; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Macrogenics; Merck; Novartis; Seagen
Research Funding - Genentech (Inst); Macrogenics (Inst); Pfizer (Inst)
 
Eric S. Winer
Consulting or Advisory Role - Jazz Pharmaceuticals; Novartis; Pfizer; Takeda
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Gad Getz
Leadership - Scorpion Therapeutics
Stock and Other Ownership Interests - Scorpion Therapeutics
Consulting or Advisory Role - Scorpion Therapeutics
Research Funding - IBM; Pharmacyclics
Patents, Royalties, Other Intellectual Property - Multiple bioinformatics patents
 
Rinath Jeselsohn
No Relationships to Disclose